NCT03870334View on ClinicalTrials.gov

Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease

PHASE2TerminatedINTERVENTIONAL

Enrollment

27

Participants

Timeline

Start Date

May 5, 2021

Primary Completion Date

August 26, 2022

Study Completion Date

August 26, 2022

Conditions

Crohn's Disease

Interventions

DRUG

BT-11 880 mg

Oral once daily tablet

DRUG

Placebo

Oral once daily tablet

Trial Locations (1)

33592

Study Center, Tampa

Sponsors

Lead Sponsor

NImmune Biopharma

All Listed Sponsors

lead

NImmune Biopharma

INDUSTRY

NCT03870334 - Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease | Biotech Hunter | Biotech Hunter